Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fernando Rivero

Showing results (131-140 of 181) with videos related to

Pageof 19
Sort By:
The American Journal of Cardiology|December 14, 2021
Procedural Results and One-Year Clinical Outcomes of Treatment of Bioresorbable Vascular Scaffolds Restenosis (from the RIBS VII Prospective Study)Fernando Alfonso, Javier Cuesta, Soledad Ojeda, et al.
The American Journal of Cardiology|January 4, 2016
Comparison of the Efficacy of Everolimus-Eluting Stents Versus Drug-Eluting Balloons in Patients With In-Stent Restenosis (from the RIBS IV and V Randomized Clinical Trials)Fernando Alfonso, María José Pérez-Vizcayno, Bruno García Del Blanco, et al.
Virchows Archiv : an International Journal of Pathology|June 25, 2013
A TP53 founder mutation, p.R337H, is associated with phyllodes breast tumors in BrazilJuliana Giacomazzi, Patricia Koehler-Santos, Edenir Inez Palmero, et al.
Coronary Artery Disease|June 20, 2020
Scoring balloon predilation before bioresorbable vascular scaffold implantation in patients with in-stent restenosis: the RIBS VI 'scoring' studyFernando Alfonso, Javier Cuesta, Bruno García Del Blanco, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|September 28, 2022
Long-term outcomes of patients with normal fractional flow reserve and thin-cap fibroatheromaEnrico Fabris, Balázs Berta, Tobias Hommels, et al.
JACC. Cardiovascular Interventions|September 4, 2017
Bioresorbable Vascular Scaffolds for Patients With In-Stent Restenosis: The RIBS VI StudyFernando Alfonso, Javier Cuesta, María José Pérez-Vizcayno, et al.
The American Journal of Cardiology|February 1, 2017
Usefulness of Drug-Eluting Balloons for Bare-Metal and Drug-Eluting In-Stent Restenosis (from the RIBS IV and V Randomized Trials)Fernando Alfonso, María José Pérez-Vizcayno, Bruno García Del Blanco, et al.
JACC. Cardiovascular Interventions|September 11, 2020
Transcatheter Aortic Valve Replacement for Residual Lesion of the Aortic Valve Following "Healed" Infective EndocarditisSandra Santos-Martínez, Abdullah Alkhodair, Luis Nombela-Franco, et al.
European Heart Journal|August 4, 2021
Thin-cap fibroatheroma predicts clinical events in diabetic patients with normal fractional flow reserve: the COMBINE OCT-FFR trialElvin Kedhi, Balazs Berta, Tomasz Roleder, et al.
Coronary Artery Disease|April 20, 2021
Clinical implications of arterial hypertension in patients with spontaneous coronary artery dissectionFernando Alfonso, Marcos García-Guimaraes, Teresa Alvarado, et al.
Pageof 19

Showing results (131-140 of 181) with videos related to

Sort By:
Pageof 19
The American Journal of Cardiology|December 14, 2021
Procedural Results and One-Year Clinical Outcomes of Treatment of Bioresorbable Vascular Scaffolds Restenosis (from the RIBS VII Prospective Study)Fernando Alfonso, Javier Cuesta, Soledad Ojeda, et al.
The American Journal of Cardiology|January 4, 2016
Comparison of the Efficacy of Everolimus-Eluting Stents Versus Drug-Eluting Balloons in Patients With In-Stent Restenosis (from the RIBS IV and V Randomized Clinical Trials)Fernando Alfonso, María José Pérez-Vizcayno, Bruno García Del Blanco, et al.
Virchows Archiv : an International Journal of Pathology|June 25, 2013
A TP53 founder mutation, p.R337H, is associated with phyllodes breast tumors in BrazilJuliana Giacomazzi, Patricia Koehler-Santos, Edenir Inez Palmero, et al.
Coronary Artery Disease|June 20, 2020
Scoring balloon predilation before bioresorbable vascular scaffold implantation in patients with in-stent restenosis: the RIBS VI 'scoring' studyFernando Alfonso, Javier Cuesta, Bruno García Del Blanco, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|September 28, 2022
Long-term outcomes of patients with normal fractional flow reserve and thin-cap fibroatheromaEnrico Fabris, Balázs Berta, Tobias Hommels, et al.
JACC. Cardiovascular Interventions|September 4, 2017
Bioresorbable Vascular Scaffolds for Patients With In-Stent Restenosis: The RIBS VI StudyFernando Alfonso, Javier Cuesta, María José Pérez-Vizcayno, et al.
The American Journal of Cardiology|February 1, 2017
Usefulness of Drug-Eluting Balloons for Bare-Metal and Drug-Eluting In-Stent Restenosis (from the RIBS IV and V Randomized Trials)Fernando Alfonso, María José Pérez-Vizcayno, Bruno García Del Blanco, et al.
JACC. Cardiovascular Interventions|September 11, 2020
Transcatheter Aortic Valve Replacement for Residual Lesion of the Aortic Valve Following "Healed" Infective EndocarditisSandra Santos-Martínez, Abdullah Alkhodair, Luis Nombela-Franco, et al.
European Heart Journal|August 4, 2021
Thin-cap fibroatheroma predicts clinical events in diabetic patients with normal fractional flow reserve: the COMBINE OCT-FFR trialElvin Kedhi, Balazs Berta, Tomasz Roleder, et al.
Coronary Artery Disease|April 20, 2021
Clinical implications of arterial hypertension in patients with spontaneous coronary artery dissectionFernando Alfonso, Marcos García-Guimaraes, Teresa Alvarado, et al.
Pageof 19